Lung Cancer | Specialty

Dr. Kris on the Future of Immunotherapy and Targeted Therapy in Lung Cancer

January 4th 2017

Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses what the future holds for the development of immunotherapy and targeted therapy in the treatment of patients with lung cancer.

Expert Emphasizes Importance of Liquid Biopsies in Lung Cancer

December 23rd 2016

Plasma- and urine-based assays designed to detect actionable mutations in patients with non–small cell lung cancer are changing the face of treatment for these patients.

Expert Discusses Challenges With Non-Driver Lung Adenocarcinoma

December 23rd 2016

Molecular testing is done for patients with non–small cell lung cancer to determine what genetic abnormalities are present. If a common-enough mutation is detected—such as EGFR or ALK—then patients are able to receive a targeted agent matched to that driver.

The Future of Driver Mutations in NSCLC

December 22nd 2016

Practical Experience With Dabrafenib/Trametinib in NCSLC

December 22nd 2016

Targeted Approaches in NSCLC: Lessons from Melanoma

December 22nd 2016

Patient Selection in BRAF-Mutant NSCLC

December 22nd 2016

The Evolving Mutational Landscape in NSCLC

December 22nd 2016

NSCLC: The BRAF/MEK Combination Safety Profile

December 22nd 2016

BRAF/MEK Efficacy in BRAF-mutant NSCLC

December 22nd 2016

Role of the MAP Kinase Pathway in NSCLC

December 22nd 2016

Outcomes With Chemotherapy in BRAF-Mutant NSCLC

December 22nd 2016

Understanding the BRAF-mutated Population in NSCLC

December 22nd 2016

Current Mutation Testing in Lung Cancer

December 22nd 2016

Osimertinib Potential Emerges in EGFR T790M-Mutant NSCLC

December 21st 2016

Osimertinib, an EGFR tyrosine kinase inhibitor (TKI), is quickly emerging as a therapeutic option for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who develop the acquired resistance mutation T790M.

Expert Highlights Ongoing Progress in ALK+ NSCLC

December 21st 2016

Frontline therapy for patients with ALK-positive non–small cell lung cancer is poised to change in the coming years, as researchers continue to explore agents beyond crizotinib.

CHMP Recommends Approval of Alectinib for ALK+ NSCLC

December 17th 2016

The Committee for Medicinal Products for Human Use has recommended approval of alectinib as a treatment for patients with metastatic ALK-positive non—small cell lung cancer following progression on crizotinib.

Frontline Pembrolizumab Receives Positive CHMP Opinion for PD-L1+ NSCLC

December 17th 2016

The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of frontline pembrolizumab for the treatment of patients with metastatic non–small cell lung cancer whose tumors do not harbor EGFR or ALK mutations.

Tolerability-Guided Dose Adjustment of Afatinib in NSCLC

December 17th 2016

Sequencing EGFR-Targeted Therapies in NSCLC

December 17th 2016